Navigation Links
A Simple Way to Detect Breast Cancer at 'Stage 0' Discovered
Date:7/22/2011

GERMANTOWN, Md., July 22, 2011 /PRNewswire/ -- RNL Natural Co., Ltd, a leading biotech company specialized in adult stem cell therapeutics affiliated with RNL BIO Co., Ltd., introduced on June 22, 2011 a new method of detecting breast cancer as early as at 'stage 0' through breath VOCs (volatile organic compounds, a predictor of breast cancer).

Researchers at RNL conducted a study of 35 women diagnosed with breast cancer and 35 healthy women not suffering from the disease. These women participated in the study using breath analysis for breast cancer detection. Results showed that this method demonstrated and visualized distinct patterns for each group, which can help physicians with screening breast cancer patients at a very early stage just by breath before diagnostic confirmation in later stages and saving more lives.

The newly developed technology was inspired from canines' ability that recognizes distinct scents in an extremely sensitive manner. Researchers explain that the machine is able to recognize patterns of VOCs.

Dr. Ra of RNL who led the research stated, "1 out of every 8 women are diagnosed with breast cancer and there has been a yearly increase of 15% of breast cancer found in women. With the breathalyzer, there is a pathway for breast cancer to be detected at the earliest stages and treatment can be started sooner."  In addition, "this method of screening is simple and painless. It is available to women who are concerned about the disease and can get tested sooner. Costs are also lower for screening and treatment through the breathalyzer."

Furthermore, "As we identified adipose stem cells' cancer suppression effect, we could establish a full lineup from early detection to cancer treatment with combining stem cell therapy with testing by the breathalyzer for breast cancer detection will be more efficient. We are continuing to find ways to prevent further progression of diseases like breast cancer through early detection and treatment," Dr. Ra added.  

This phenomenal breakthrough in technology is patent pending and will be published by the end of this year.

About RNL Group

RNL Bio is a premier biopharmaceutical company focused on development and commercialization of early cancer detection, cancer vaccine and adult stem cell therapeutics. Headquartered in Seoul with state-of-the-art GMP facility, RNL is publicly traded company on the Korea Exchange (Code 003190) and strives to become a global leader across the biomedical industry.

RNL Life Science is a majority owned subsidiary of RNL BIO. It distributes RNL group's technology and products in American market.


'/>"/>
SOURCE RNL Natural Co., Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simple Test Accurately Predicts Risk of Serious Jaundice in Newborns
2. American Lung Association Offers Simple Tips to Protect Public Health and Minimize H1N1 Flu (Swine Flu) and Seasonal Flu Transmission
3. Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ)
4. 2009 H1N1 Flu Test From Quest Diagnostics Now CE Marked For International Distribution Under The Simplexa(TM) Brand Name
5. Researchers Announce Medical Breakthrough with Simple, Inexpensive Blood Test for Colon Cancer
6. Bayer Express Your Simple Win Creativity Contest Grand Prize Winners Announced
7. arGEN-X SIMPLE Antibody(TM) Platform set to Transform Therapeutic Antibody Discovery & Development
8. Sensitechs Groundbreaking TempTale(R)4 USB Dry Ice Temperature Monitor Provides Fast, Simple, Efficient Cold Chain Visibility
9. Medco, Mayo Clinic Study Reveals Using a Simple Genetic Test Reduces Hospitalization Rates by Nearly a Third for Patients on Widely Prescribed Blood Thinner
10. arGEN-X Granted Broad Patent Covering its Unique SIMPLE Antibody(TM) Platform
11. Group Practice Forum Launches Fromer-GPF Patient Journey Providing Physicians with Simple Solutions to Improve Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016 ... accelerator (MR-linac) platform will be the focal point of ... of the European Society for Radiotherapy & Oncology, taking ... MR-linac integrates a state-of-the-art radiotherapy system and a high-field ... to clearly see the patient,s anatomy in real time. ...
(Date:4/27/2016)... -- Shire plc (LSE: SHP, NASDAQ: ... Officer, will present at the Deutsche Bank 41st Annual Health ... Wednesday, May 04, 2016, 10:00 am EDT (15:00 BST). ... Presentations and Webcasts section of Shire,s Investor website at ... available on this same website for approximately 90 days. ...
(Date:4/27/2016)... At the Sachs CEO forum ... Phase 2 clinical study of its lead drug candidate, ... implantation (CI) surgery. This large, placebo-controlled, double-blind, phase 2 ... and France . STR001 ... time of surgery. "Despite advances in cochlear implant technology, ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 2016 , ... Mercy College is expanding its Graduate Business Programs to the ... due to high demand: Master of Business Administration (MBA), Master of Organizational Leadership (MSOL) ... , School of Business Graduate Program Chair Dr. Ray Manganelli said: “We believe that ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... , announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula ... brain and mood optimization products to the store is just one more way ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Bernie Siegel, ... "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death live on ... Dr. Bernie Siegel, author of a plethora of essential books-to-read for physicians ...
(Date:4/29/2016)... Petersburg, Fla. (PRWEB) , ... April 29, 2016 ... ... Children’s Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia have ... babies is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails ...
(Date:4/29/2016)... York, NY (PRWEB) , ... April 29, 2016 ... ... manufacturer and engineer of patented products, announces the Gyrociser, an exercise invention which ... is worth $2 billion," says Scott Cooper, CEO and Creative Director of World ...
Breaking Medicine News(10 mins):